Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Clinical Trials (London, England)|January 16, 2016
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challengesAn Vandebosch, Robin Mogg, Nele Goeyvaerts, et al.
Plos One|July 20, 2018
Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trialPaul Meyvisch, Chrispin Kambili, Koen Andries, et al.
Clinical Therapeutics|February 10, 2015
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitorDamayanthi Devineni, Christopher R Curtin, Thomas C Marbury, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaStefaan Rossenu, Adriaan Cleton, David Hough, et al.
Journal of Clinical Pharmacology|March 29, 2014
A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaAdriaan Cleton, Stefaan Rossenu, Herta Crauwels, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participantsDamayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, et al.
NPJ Vaccines|May 21, 2026
The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccinesMariska G M van Rosmalen, Joris Menten, Daniel J Stieh, et al.
The Journal of Infectious Diseases|January 5, 2021
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge StudyJerald Sadoff, Els De Paepe, John DeVincenzo, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
BMC Gastroenterology|February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infectionStefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Pageof 4